FDA Recommended Additional Trial for Compass Therapeutics Drug
The FDA advised Compass Therapeutics to demonstrate a survival benefit before seeking approval for its cancer drug, tovecimig.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Should regulators expedite drug approvals even if long-term survival data is currently incomplete?
The FDA has recommended that Compass Therapeutics conduct a survival benefit trial before submitting a Biologics License Application (BLA) for its investigational drug, tovecimig. Compass Therapeutics has expressed disagreement with the necessity of an additional study, citing current phase 2/3 trial data as sufficient evidence.
Why it matters
The company argues that existing data supports an accelerated BLA submission to address the urgent unmet medical needs of patients with biliary tract cancer. A resolution between the agency and the developer is critical to determining the future availability of this targeted therapy.
The COMPANION-002 study reported a 4.7-month median progression-free survival for tovecimig patients versus 2.6 months for those receiving only paclitaxel. The trial also recorded a hazard ratio of 0.44 and a p-value of 0.0228 for response rates.
The players
Compass Therapeutics
This is a clinical-stage biopharmaceutical company headquartered in Boston that focuses on developing proprietary antibody-based therapeutics for cancer.
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by regulating the safety and efficacy of medical products in the United States.
The details
Tovecimig is an investigational DLL4 x VEGF-A bispecific antibody designed to disrupt tumor growth by blocking two angiogenic pathways simultaneously. Compass Therapeutics, based in Boston, intends to consult with the FDA to discuss a path forward for its regulatory filing.
Timeline
September 22, 2026: Compass Therapeutics announced the regulatory feedback received from the FDA.
The Big Picture
The FDA's decision regarding the tovecimig submission process highlights the strict evidentiary requirements of the FDA Accelerated Approval pathway, which is often used for drugs treating serious conditions. This dispute marks a departure from standard expectations where early-stage positive efficacy data might typically suffice for a regulatory submission.
Patients with biliary tract cancer currently face limited treatment options, making the availability of tovecimig a significant potential health milestone. Future regulatory outcomes will directly determine if this investigational bispecific antibody becomes an accessible therapy option.
The takeaway
Patients and their families should discuss evolving treatment options and clinical trial eligibility with their oncology teams during the regulatory review process. Engaging with clinical research centers can provide access to emerging therapies while larger approval timelines are being navigated.
Further reading
For more background on ongoing research, visit the Cancer section.
Live Poll
Should regulators expedite drug approvals even if long-term survival data is currently incomplete?
